Data Insights

Olverembatinib by Ascentage Pharma Group International for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Myelocytic Leukemia (CML,...

Likelihood of Approval and Phase Transition Success Rate Model - Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

Lisaftoclax by Ascentage Pharma Group International for Refractory Multiple Myeloma: Likelihood of Approval

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Refractory Multiple Myeloma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lisaftoclax in Refractory Multiple Myeloma

Data Insights

Lisaftoclax by Ascentage Pharma Group International for Relapsed Multiple Myeloma: Likelihood of Approval

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Relapsed Multiple Myeloma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Lisaftoclax in Relapsed Multiple Myeloma

Data Insights

Lisaftoclax by Ascentage Pharma Group International for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase III for Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Lisaftoclax in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Lisaftoclax by Ascentage Pharma Group International for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Acute Myelocytic Leukemia (AML,...

Likelihood of Approval and Phase Transition Success Rate Model - Lisaftoclax in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

APG-2449 by Ascentage Pharma Group International for Ovarian Cancer: Likelihood of Approval

APG-2449 is under clinical development by Ascentage Pharma Group International and currently in Phase II for Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - APG-2449 in Ovarian Cancer

Data Insights

APG-2449 by Ascentage Pharma Group International for Fallopian Tube Cancer: Likelihood of Approval

APG-2449 is under clinical development by Ascentage Pharma Group International and currently in Phase II for Fallopian Tube Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - APG-2449 in Fallopian Tube Cancer

Data Insights

APG-2449 by Ascentage Pharma Group International for Peritoneal Cancer: Likelihood of Approval

APG-2449 is under clinical development by Ascentage Pharma Group International and currently in Phase II for Peritoneal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - APG-2449 in Peritoneal Cancer

Data Insights

Alrizomadlin by Ascentage Pharma Group International for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval

Alrizomadlin is under clinical development by Ascentage Pharma Group International and currently in Phase II for Adenoid Cystic Carcinoma (ACC)....

Likelihood of Approval and Phase Transition Success Rate Model - Alrizomadlin in Adenoid Cystic Carcinoma (ACC)